In London, Astraazeneca Cascal, shown in London, is described in London on June 28, 2023 in London, which wants to change the company’s listing from London to the United States.
Justin Taluan | AFP | Getty images
Pressure on the London Stock Exchange with reports on the British Pharma Giant AstraZeneca Can ship another blow this week to the US.
Top-Pascal Soriot is considering the company’s listing of the company from London to the United States to the United States and British newspapers Order After the afternoon, there was a link to anonymous sources. The protest of the soriot to the UK’s regulatory environment is especially evident in the approval of new drugs and drug quotations.
Refused to comment in the Astrazeneca report.
The company’s exit from the UK market creates great weight of Strany, which is the most valuable business in the FTSE 100 of London. According to LSEG, AstraZeneca’s cover is 161.2 billion tenge by closing price on Tuesday. Dollars ($ 221.1 billion).
The potential transatlantic movement of Astrazeneca would be concerned about the status of weakening London as a global financial hub. A number of companies crossed the London market and reconsidered the shares in the city last year.
Tony Meads, London’s Briese wealth, said that Astrazene has noted the “disappointing” market market, but he called “not surprisingly”, but it is in the last created process.
Early this year, Reports appeared This is the list in Hong Kong instead of London, which is in place in Hong Kong instead of London. Reuters news agency last week Messages The company plans to apply confidentially for Hong Kong for IPO.
Metals Investor Cobalt Holdings, which were confirmed to CNBC, which is a London IPO, and British Fintech GIANAND is smart Published in June This listed his first list to New York from London.
Christo Kauarn, smart kauen and a joint justification, according to the statement, helps to increase the company’s awareness of the company in the United States, achieving this step in the “deepest and liquid capital market in the world.”
Subscribe now
Companies listed in London have historically lower prices than their wall colleagues. Exploration Last year, last year Ratbones showed that last year the interest rate for the UK funds for the UK funds showed that we are 32% lower than in the United States.
In FIPSIDE, Financial Times Messages Last week, the Norwegian software chose a giant visa for choosing London in the general market in the future.
“Large and important companies such as Astazeneka are looking for an assessment of the spacious investor database, because they have been moving to the United States on the transition to the United States, because they told CNBC on Wednesday.
“The trends of the listing, or the current stake in the UK, show values in the UK market, but do not include the list of new companies in the new context of these countries to support the future of the index,” he added.
‘Britain loses his edge’
Claier Tractet, M & A, the founder of the consultative trachet, said that AstraZeneca has stated that the London Stock Exchange has stated a “memorable loss”.
“Taking into account the complexity of the company, it is often due to the housing or assessment benefits, mostly by means of regulatory framework, regulatory restrictions, regulatory restrictions, regulatory restrictions and industrial stimulus and industrial stimulus. By e-mail to CNBC.
Traffet Listing companies who have listed over 100 billion dollars in recent years have said that in recent years, New York to New York, and the lonse of Astrazeneca will be twice as much.
“A potential step is that the world’s world-class needs will make it difficult for global markets about the needs of large-scale companies,” he said. “It’s not a isolated event – and this is not the biggest problem. This is part of a wide range, and the founders and boards have a foundation of deeper capital, strong support and ambitious. “
Tom Bacon, M & A and Corporate Finance Department, the desire of Lons Bacon – from Lons Bacon – from London from London, which is called London, was called “very disturbing”.
“I think it is necessary to do more to support the city and our stock market with critical productions such as life sciences and pharmaceuticals,” he said.
List change ‘cannot move easily to attract’
Dan Cottonth in Bell, Dan Cottonth, Wednesday Investment Analyzer stated that it is not easy to move the company through “Atlantic” by “Atlantic” than “Atlantic” than to chase a high assessment.
“Unlike many other parts of the United Kingdom, the United States has an oversized joint-stock base, ie AstraZeneca has a geographical fund,” he explained in the email.
However, Puckots noted that AstraZeneca is about 42% of US sales from US to about 42% of the United States and to increase operating tracking in the country.
Early this year, soriot CNBC said AstraZeneca is “very loyal to the United States”, where there are two major research centers of the company.
AJ Bell’s coat said at CNBC, the General Director of Astraazeneca believed that the US believed that the United States is full of “gems for the best sides of treatment.”
European pharmaceutical companies are uncertain around their future, where US President Donald Trump threatened to set tariffs for drug imports.
Although the industry is released from Trump, called complex tariffs, when opened in April, the head of the White House has ever been placed sector with investigation US Department of Trade, warned Pharma tariffs are “recently coming” and Executive order signed To reduce medical drugs to reduce some drug prices in accordance with costs paid abroad.
